FINWIRES · TerminalLIVE
FINWIRES

美國油價最新消息:布蘭特原油價格觸及三週高位,和平談判陷入僵局

By

-- 週一,油價上漲,布蘭特原油價格觸及近三週高位,因為和平談判陷入僵局,霍爾木茲海峽持續關閉,導致全球原油供應趨緊。 近月西德州中質原油期貨上漲0.6%,至每桶94.95美元;布蘭特原油期貨上漲0.9%,至每桶106.25美元。 盛寶銀行分析師表示:“由於霍爾木茲海峽實際上仍然關閉,油價持續走高,中東地區的混亂局面不斷加劇,導致從原油、燃料和天然氣到金屬、化肥和石化產品等關鍵大宗商品的供應持續緊張。” “由於重啟和平談判的努力陷入僵局,布倫特原油價格觸及三週高位。據報道,伊朗提出的方案要求將核談判推遲到後期。” 隨著高盛和埃尼大幅上調預測,市場目前已將關鍵能源走廊長期對峙的預期計入價格。 分析師指出,高盛將第四季布蘭特原油價格預期上調至每桶90美元,高於先前預測的80美元,也高於目前88美元的交易均價。 義大利能源巨頭埃尼(E)警告稱,市場低估了衝突的持續時間,並將2026年布蘭特原油價格預期上調至每桶83美元。 上週市場情緒發生巨大轉變,市場對衝突即將結束的預期更加悲觀。布蘭特原油週漲幅達17%,WTI原油漲幅超過13%。

Related Articles

Treasury

Scotiabank Previews This Week's February and Preliminary March GDP for Canada

Canada reports gross domestic product for February and the preliminary estimate for March on Thursday, said Scotiabank.February was initially guided by Statistics Canada to have been tracking a 0.2% month-over-month gain last month. Updated estimates are still in the same ballpark, but investors also get important details on sector drivers, noted the bank.More meaningful may be the flash guidance, with no details, for March GDP, for which there is very little information so far, but a small gain is "feasible," stated Scotiabank.The outcome will further inform Q1 GDP growth tracking on a production/income basis using monthly GDP. It's feasible that growth is tracking close to the Bank of Canada's 1.8% January Monetary Policy Report estimate, but that's on an expenditure basis. The massive over 4% inventory drag on Q4 GDP could reverse as an added upside, pointed out the bank.One key is that consumer spending on goods is tracking a strong rebound in Q1 based on retail sales volumes. It's untrue that the economy isn't exhibiting rate sensitivity, a view that is disproportionately driven by a false understanding of what's keeping condo markets weak in Toronto and Vancouver, added Scotiabank.

$$CXY
Australia

Vicor Insider Sold Shares Worth $2,079,226, According to a Recent SEC Filing

Alvaro Doyle, Vice President and Chief Information Officer, on April 23, 2026, sold 8,000 shares in Vicor (VICR) for $2,079,226. Following the Form 4 filing with the SEC, Doyle has control over a total of 42 common shares of the company, with 42 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/751978/000182673026000002/xslF345X05/primary_doc.xmlPrice: $265.29, Change: $-8.24, Percent Change: -3.01%

$VICR
Australia

BioMarin Seen Building Broader Rare-Disease Platform After Amicus Deal, Morgan Stanley Says

BioMarin Pharmaceutical (BMRN) is emerging as a broader rare-disease platform as its acquisition of Amicus Therapeutics (FOLD) adds two approved medicines and reduces reliance on Voxzogo, Morgan Stanley said Monday in a report.The Amicus deal reshapes BioMarin's outlook by adding Galafold and Pombiliti with Opfolda, products that fit the company's global commercial network, the report said. The therapies are expected to generate more than $1.3 billion in revenue by 2030, Morgan Stanley said.The acquisition is projected to accelerate revenue growth immediately after closing and to be accretive to non-GAAP earnings within 12 months, with "substantial accretion" beginning in 2027, the report said. BioMarin closed its $4.8 billion purchase of Amicus on Monday.Morgan Stanley resumed coverage on BioMarin stock with an overweight rating and a $120 price target.Price: $54.08, Change: $+0.90, Percent Change: +1.68%

$BMRN$FOLD